yupa-watchanakit-shutterstock-com
Yupa Watchanakit / Shutterstock.com
23 September 2015Americas

BioMarin and Dr Reddy’s settle Kuvan row

US biotechnology company BioMarin Pharmaceutical has agreed to settle its patent infringement lawsuit against Dr Reddy’s Laboratories centring on its Kuvan (sapropterin dihydrochloride) drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 April 2021   Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.

More on this story

Americas
29 April 2021   Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.

More on this story

Americas
29 April 2021   Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit.